---
title: "Citius Pharmaceuticals, Inc. (CTXR.US)"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/CTXR.US.md"
symbol: "CTXR.US"
name: "Citius Pharmaceuticals, Inc."
industry: "Pharmaceuticals"
datetime: "2026-05-21T11:54:23.995Z"
locales:
  - [en](https://longbridge.com/en/quote/CTXR.US.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/CTXR.US.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/CTXR.US.md)
---

# Citius Pharmaceuticals, Inc. (CTXR.US)

## Company Overview

Citius Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of critical care products. Its LYMPHIR, an FDA-approved product, is a targeted immunotherapy for the treatment of cutaneous T-cell lymphoma. The company’s late-stage pipeline includes Mino-Lok, an antibiotic lock solution to treat patients with catheter-related bloodstream infections; Halo-Lido, a corticosteroid-lidocaine topical formulation to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids; and NoveCite, a mesenchymal stem cell therapy for the treatment of ARDS. Citius Pharmaceuticals, Inc.

| Item | Detail |
|------|--------|
| Industry | Pharmaceuticals |
| Exchange | US Market |
| Website | [citiuspharma.com](https://citiuspharma.com) |

## Key Drivers
> *AI-analyzed key factors driving this stock's performance*


## Longbridge Financial Score™: D
> *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge*
> Updated: 2026-05-21T04:30:19.000Z

**Overall: D (0.60)**

**Industry**: Pharmaceuticals

| Metric | Value |
|--------|-------|
| Industry Ranking | 0 / 190 |
| Industry Median | C |
| Industry Average | C |

- **Style**: Value - Stocks where the company's main business is in a mature stage.
- **Scale**: Small - The company's operation has a high degree of growth and volatility, making it easy to achieve high investment returns.

**Multi Score**: D

#### Style Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | 0.00% |  |
| Net Profit YoY | 0.00% |  |
| P/B Ratio | 0.21 |  |
| Dividend Ratio | 0.00% |  |

#### Size Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 12978327.66 |  |
| Revenue | 5611409.00 |  |

#### Multi Score Score: D

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | -49.37% | E |
| Profit Margin | -909.87% | E |
| Gross Margin | 79.99% | A |
| Revenue YoY | 0.00% | C |
| Net Profit YoY | 11.88% | C |
| Total Assets YoY | 16.31% | B |
| Net Assets YoY | 35.62% | A |
| Cash Flow Margin | 97.07% | C |
| OCF YoY | 0.00% | D |
| Turnover | 0.03 | E |
| Gearing Ratio | 33.42% | B |

```chart-data:radar
{
  "title": "Longbridge Financial Score - Citius Pharmaceuticals, Inc.",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Style Score",
      "grade": "",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "0.00%",
          "rating": ""
        },
        {
          "name": "Net Profit YoY",
          "value": "0.00%",
          "rating": ""
        },
        {
          "name": "P/B Ratio",
          "value": "0.21",
          "rating": ""
        },
        {
          "name": "Dividend Ratio",
          "value": "0.00%",
          "rating": ""
        }
      ]
    },
    {
      "name": "Size Score",
      "grade": "",
      "indicators": [
        {
          "name": "Market Cap",
          "value": "12978327.66",
          "rating": ""
        },
        {
          "name": "Revenue",
          "value": "5611409.00",
          "rating": ""
        }
      ]
    },
    {
      "name": "Multi Score",
      "grade": "D",
      "indicators": [
        {
          "name": "ROE",
          "value": "-49.37%",
          "rating": "E"
        },
        {
          "name": "Profit Margin",
          "value": "-909.87%",
          "rating": "E"
        },
        {
          "name": "Gross Margin",
          "value": "79.99%",
          "rating": "A"
        },
        {
          "name": "Revenue YoY",
          "value": "0.00%",
          "rating": "C"
        },
        {
          "name": "Net Profit YoY",
          "value": "11.88%",
          "rating": "C"
        },
        {
          "name": "Total Assets YoY",
          "value": "16.31%",
          "rating": "B"
        },
        {
          "name": "Net Assets YoY",
          "value": "35.62%",
          "rating": "A"
        },
        {
          "name": "Cash Flow Margin",
          "value": "97.07%",
          "rating": "C"
        },
        {
          "name": "OCF YoY",
          "value": "0.00%",
          "rating": "D"
        },
        {
          "name": "Turnover",
          "value": "0.03",
          "rating": "E"
        },
        {
          "name": "Gearing Ratio",
          "value": "33.42%",
          "rating": "B"
        }
      ]
    }
  ]
}
```

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | -0.28 | 77/190 | - | - | - |
| PB | 0.21 | 9/190 | 0.33 | 0.26 | 0.21 |
| PS (TTM) | 2.31 | 64/190 | 4.85 | 4.28 | 3.90 |
| Dividend Yield | 0.00% | - | - | - | - |

## Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 01 | Cormedix (CRMD.US) | A | A | B | C | B | A |
| 02 | Eli Lilly (LLY.US) | A | A | B | D | B | B |
| 03 | ROCHE HOLDINGS AG (RHHVF.US) | A | B | B | D | B | B |
| 04 | Roche (RHHBY.US) | A | B | B | D | B | B |
| 05 | AstraZeneca (AZN.US) | A | B | C | D | B | B |

## Institutional View

### Analyst Rating Distribution

> As of 2026-05-18T04:00:00.000Z

Total Analysts: **2**

| Rating | Count | Percentage |
|--------|-------|-----------| 
| Buy | 2 | 100% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 0.58 |
| Highest Target | 6.00 |
| Lowest Target | 6.00 |

## References

- [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/CTXR.US/overview.md)
- [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/CTXR.US/norm.md)
- [Related News](https://longbridge.com/en/quote/CTXR.US/news.md)
- [Filings — Company announcements and regulatory filings](https://longbridge.com/en/quote/CTXR.US/filings.md)

---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**